Back to top
more

Baxter International (BAX)

(Real Time Quote from BATS)

$35.97 USD

35.97
2,818,126

-0.94 (-2.55%)

Updated Oct 2, 2024 03:17 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues

by Zacks Equity Research

Strong performance in the Instruments & Accessories and Systems segments drive Intuitive Surgical's (ISRG) top line in Q3.

Will Edwards' (EW) Steady Overall Growth Drive Q3 Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q3.

Can Overall Growth Drive Align Technology (ALGN) Q3 Earnings?

by Zacks Equity Research

Align Technology (ALGN) likely to gain from strength in Invisalign space as well as Scanner and Service business in Q3.

Will 5 Elements Drive Quest Diagnostics (DGX) Q3 Earnings?

by Zacks Equity Research

Quest Diagnostics' (DGX) growing partnerships with health care leaders and strategic acquisitions are expected to boost top and bottom-line growth in Q3.

Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed

by Zacks Equity Research

Within Structural Heart, growth was driven by several product areas across Abbott's (ABT) broad portfolio, including AMPLATZER PFO Occluder and MitraClip.

Can Solid Overall Growth Drive Illumina (ILMN) Q3 Earnings?

by Zacks Equity Research

Illumina (ILMN) is likely to gain from strong revenues at the Product, Service and other segments in Q3.

What's in Store for Cerner (CERN) This Earnings Season?

by Zacks Equity Research

Cerner's (CERN) third-quarter 2018 results are likely to be hurt by soft segmental results; guidance promising.

    Will Instruments Drive Intuitive Surgical (ISRG) Q3 Earnings?

    by Zacks Equity Research

    Strong prospects in the Instruments and Accessories segment to drive Intuitive Surgical???s (ISRG) top line in the third quarter of 2018.

      Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?

      by Zacks Equity Research

      Solid prospects in the Oncology segment to boost Varian Medical's (VAR) top-line performance in the fourth quarter of fiscal 2018.

      What's in Store for Express Scripts' (ESRX) Q3 Earnings?

      by Zacks Equity Research

      Express Scripts (ESRX) likely to see soft PBM revenues in the third quarter of 2018; guidance strong.

        Cerner's Millennium Platform Integrated at McLaren Hospital

        by Zacks Equity Research

        Cerner's (CERN) Millennium HCIT platform sees a series of developments in 2018.

        Can Baxter (BAX) Keep the Earnings Surprise Streak Alive?

        by Zacks Equity Research

        Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

        Baxter & ASPEN Launch PN Tools to Boost Clinical Nutrition

        by Zacks Equity Research

        Baxter (BAX) and ASPEN's SmartPN lends the company a competitive edge in the MedTech space.

        Zacks.com highlights: Lululemon Athletica, Malibu Boats, Surmodics and Baxter International

        by Zacks Equity Research

        Zacks.com highlights: Lululemon Athletica, Malibu Boats, Surmodics and Baxter International

          Tirthankar Chakraborty headshot

          Buy These 4 Efficient Stocks for Stellar Returns

          by Tirthankar Chakraborty

          A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

            Stryker's HyperBranch Buyout to Boost Neurotechnology Business

            by Zacks Equity Research

            Stryker's (SYK) craniomaxillofacial division's market prospects bright.

              Baxter Collaborates With Mayo Clinic to Open Renal Care Center

              by Zacks Equity Research

              Per the agreement, Baxter (BAX) and Mayo Clinic researchers to form an outpatient clinic for kidney disease management, home dialysis and in-center dialysis services.

                Baxter (BAX) Collaborates With USC CBC to Digitize Healthcare

                by Zacks Equity Research

                Baxter's (BAX) efforts to digitize healthcare solutions are likely to fortify its foothold in the highly competitive MedTech industry.

                  Stock Market News For Sep 27, 2018

                  by Zacks Equity Research

                  Wall Street ended lower on Wednesday following quarter point interest rate hike by the Fed.

                    Baxter's (BAX) ALTAPORE Bioactive Bone Graft Gets FDA Nod

                    by Zacks Equity Research

                    Baxter's (BAX) offers a broad spectrum of surgical products, including bone grafts and substitutes that see lucrative market prospects.

                      Accuray's CyberKnife Manages Prostate Cancer Effectively

                      by Zacks Equity Research

                      Accuray's (ARAY) flagship CyberKnife is the only robotic radiotherapy system.

                        Here's Why You Should Buy Baxter International (BAX) Now

                        by Zacks Equity Research

                        Baxter's (BAX) raised guidance for 2018 and a series of approvals make it a promising investment pick.

                          Kevin Cook headshot

                          Bull of the Day: Penumbra (PEN)

                          by Kevin Cook

                          Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech

                            Stock Market News For Sept 7, 2018

                            by Zacks Equity Research

                            U.S. stock market closed mostly lower on Thursday as softness in tech sector, trade war concerns and fear of contagion from some emerging markets problems have rattled investor confidence

                              Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod

                              by Zacks Equity Research

                              The latest FDA approval for Baxter's (BAX) Actifuse Flow bone graft is likely to boost its Advanced Surgery segment.